
  
    
      
        Introduction_NNP
        The_DT use_NN of_IN inhaled_JJ bronchodilators_NNS to_TO treat_VB children_NNS
        with_IN bronchiolitis_NNS remains_VBZ controversial_JJ [_NN 1_CD ,_, 2_CD ,_, 3_CD ,_, 4_CD ]_NN ._. The_DT
        controversy_NN may_MD be_VB the_DT result_NN of_IN differences_NNS in_IN study_NN
        populations_NNS ,_, in_IN choice_NN of_IN bronchodilators_NNS ,_, or_CC in_IN measured_VBN
        outcome_NN variables_NNS between_IN trials_NNS ._. One_CD common_JJ confounding_VBG
        variable_NN of_IN past_JJ studies_NNS has_VBZ been_VBN the_DT inclusion_NN of_IN children_NNS
        with_IN a_DT history_NN of_IN recurrent_JJ wheezing_VBG ._.
        The_DT measurement_NN of_IN pulmonary_JJ function_NN during_IN infancy_NN is_VBZ
        difficult_JJ because_IN of_IN the_DT lack_NN of_IN subject_JJ cooperation_NN ._. It_PRP
        has_VBZ been_VBN shown_VBN that_DT analysis_NN of_IN flow-volume_JJ loops_NNS at_IN tidal_JJ
        breathing_NN is_VBZ useful_JJ in_IN evaluating_VBG lung_NN function_NN in_IN infancy_NN
        [_NN 5_CD ,_, 6_CD ,_, 7_CD ]_NN ._. Morris_NNP and_CC Lane_NNP [_NN 8_CD ]_NN described_VBD a_DT rapid_JJ rise_NN of_IN
        tidal_JJ expiratory_NN flow_NN to_TO a_DT maximum_NN value_NN in_IN adult_NN patients_NNS
        with_IN airflow_NN obstruction_NN ._. In_IN their_PRP$ study_NN ,_, the_DT ratio_NN of_IN the_DT
        time_NN to_TO PTEF_NNP to_TO total_VB expiratory_NN time_NN (_( 
        t_NN 
        PTEF_NNP /_NN 
        t_NN 
        E_NNP )_) and_CC the_DT ratio_NN of_IN the_DT tidal_JJ volume_NN at_IN
        PTEF_NNP to_TO total_NN exhaled_VBD volume_NN (_( 
        V_NNP 
        PTEF_NNP /_NN 
        V_NNP 
        E_NNP )_) were_VBD correlated_JJ with_IN conventional_JJ
        measurements_NNS of_IN airway_NN obstruction_NN [_NN 8_CD ]_NN ._.
        Studies_NNS have_VBP also_RB used_VBN tidal_JJ breathing_NN flow-volume_JJ
        (_( TBFV_NNP )_) loops_NNS to_TO evaluate_VB airway_NN function_NN in_IN healthy_JJ
        newborns_NNS and_CC infants_NNS with_IN and_CC without_IN wheezing_VBG [_NN 5_CD ,_, 6_CD ,_, 7_CD ,_,
        9_CD ,_, 10_CD ,_, 11_CD ,_, 12_CD ,_, 13_CD ]_NN ._. Cutrera_NNP 
        et_CC al_NN ._. [_NN 14_CD ]_NN reported_VBD a_DT good_JJ
        correlation_NN between_IN tidal_JJ expiratory_NN flow_NN patterns_NNS and_CC
        conventional_JJ spirometric_JJ measurements_NNS in_IN school-age_JJ
        children_NNS ._. Analysis_NNP of_IN tidal_JJ breathing_NN was_VBD used_VBN to_TO predict_VB
        wheezing_VBG illness_NN during_IN infancy_NN [_NN 9_CD ,_, 10_CD ,_, 13_CD ]_NN ._. Respiratory_JJ
        function_NN in_IN infants_NNS after_IN respiratory_JJ syncytial_NN virus_NN
        (_( RSV_NNP )_) -_: proven_VBN bronchiolitis_NNS showed_VBD a_DT lower_JJR 
        t_NN 
        PTEF_NNP /_NN 
        t_NN 
        E_NNP ratio_NN compared_VBN with_IN that_DT of_IN
        age-matched_JJ healthy_JJ infants_NNS [_NN 15_CD ]_NN ._.
        Several_JJ groups_NNS have_VBP studied_VBN pulmonary_JJ function_NN in_IN
        infants_NNS with_IN bronchiolitis_NNS ,_, with_IN varying_VBG results_NNS [_NN 1_CD ,_, 2_CD ,_,
        3_CD ]_NN ._. The_DT recent_JJ literature_NN also_RB suggests_VBZ either_CC a_DT lack_NN of_IN
        efficacy_NN or_CC a_DT very_RB small_JJ efficacy_NN for_IN albuterol_NN
        administration_NN in_IN the_DT management_NN of_IN bronchiolitis_NNS [_NN 16_CD ,_,
        17_CD ]_NN ._. The_DT purpose_NN of_IN the_DT present_JJ study_NN is_VBZ to_TO evaluate_VB the_DT
        effect_NN of_IN nebulized_JJ albuterol_NN administration_NN on_IN TBFV_NNP loops_NNS
        and_CC wheeze_NN scores_NNS in_IN infants_NNS with_IN bronchiolitis_NNS due_JJ to_TO
        RSV_NNP ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Selection_NN of_IN patients_NNS
          The_DT study_NN was_VBD conducted_VBN in_IN the_DT pediatric_JJ unit_NN of_IN a_DT
          community_NN teaching_NN hospital_NN ._. Patients_NNS admitted_VBD to_TO the_DT
          pediatric_JJ unit_NN were_VBD eligible_JJ for_IN the_DT study_NN if_IN they_PRP met_VBD
          the_DT following_JJ criteria_NNS :_: age_NN younger_JJR than_IN 1_CD year_NN ;_: first_JJ
          episode_NN of_IN wheezing_VBG ;_: clinical_JJ features_NNS of_IN bronchiolitis_NNS
          (_( rhinorrhea_NN ,_, tachypnea_NN ,_, and_CC wheezing_VBG and_CC /_NN or_CC rales_NNS )_) ;_: and_CC
          nasopharyngeal_NN secretions_NNS positive_JJ for_IN RSV_NNP as_IN determined_VBN
          by_IN enzyme_NN immunoassay_NN ._. Preterm_NNP infants_NNS and_CC infants_NNS with_IN
          underlying_VBG cardiopulmonary_JJ disease_NN ,_, bronchopulmonary_JJ
          dysplasia_NN ,_, previous_JJ history_NN of_IN wheezing_VBG ,_, or_CC those_DT needing_VBG
          admission_NN to_TO the_DT pediatric_JJ intensive_JJ care_NN unit_NN were_VBD
          excluded_VBN from_IN the_DT study_NN ._. The_DT study_NN was_VBD approved_VBN by_IN the_DT
          hospital_NN 's_POS Institutional_NNP Review_NNP Board_NNP ._. Informed_NNP ,_, written_VBN
          consent_NN was_VBD obtained_VBN from_IN all_DT parents_NNS before_IN enrollment_NN
          of_IN patients_NNS ._.
        
        
          Study_NN design_NN
          Eligible_NNP patients_NNS were_VBD randomly_RB assigned_VBN to_TO receive_VB
          either_CC 0_CD ._. 15_CD mg_NN /_NN kg_NN albuterol_NN in_IN 3_CD ml_NN saline_NN (_( group_NN A_DT )_) or_CC 3_CD
          ml_NN saline_NN without_IN albuterol_NN (_( group_NN B_NNP )_) via_IN a_DT nebulizer_NN
          with_IN an_DT air_NN flow_NN of_IN 6_CD -_: 8_CD l_NN /_NN min_NN ._. The_DT same_JJ patients_NNS were_VBD
          crossed-over_JJ to_TO receive_VB the_DT alternate_JJ saline_NN or_CC albuterol_NN
          treatment_NN 6_CD hours_NNS after_IN the_DT first_JJ aerosol_NN administration_NN ._.
          The_DT 6_CD hour_NN interval_NN before_IN crossover_NN measurements_NNS was_VBD
          used_VBN to_TO exclude_VB any_DT carryover_NN effect_NN of_IN nebulized_JJ
          albuterol_NN or_CC saline_NN ._. The_DT timing_NN of_IN postaerosol_NN
          measurements_NNS was_VBD based_VBN on_IN several_JJ previously_RB published_VBN
          reports_NNS [_NN 2_CD ,_, 4_CD ,_, 18_CD ,_, 19_CD ]_NN ._. Observers_NNS were_VBD unable_JJ to_TO
          distinguish_VB between_IN the_DT two_CD nebulizer_NN solutions_NNS by_IN any_DT
          characteristics_NNS ,_, and_CC both_DT nebulized_JJ solutions_NNS were_VBD
          dispensed_VBD by_IN the_DT pharmacy_NN in_IN identical_JJ syringes_NNS ._. Block_NN
          randomization_NN was_VBD also_RB performed_VBN by_IN the_DT pharmacy_NN
          department_NN and_CC the_DT records_NNS were_VBD concealed_VBN until_IN the_DT end_NN
          of_IN the_DT study_NN ._.
          Chloral_NNP hydrate_NN (_( 50_CD mg_NN /_NN kg_NN ,_, orally_RB )_) was_VBD administered_VBN 30_CD
          min_NN before_IN the_DT measurements_NNS were_VBD taken_VBN ._. An_DT aerosol_NN
          (_( either_CC albuterol_NN or_CC saline_NN )_) treatment_NN was_VBD given_VBN
          following_VBG baseline_NN measurements_NNS of_IN heart_NN rate_NN ,_,
          respiratory_JJ rate_NN ,_, wheeze_NN score_NN ,_, arterial_NN oxygen_NN
          saturation_NN by_IN pulse_NN oximetry_NN ,_, and_CC pulmonary_JJ function_NN ._. The_DT
          same_JJ measurements_NNS were_VBD also_RB repeated_VBN 15_CD min_NN after_IN the_DT
          aerosol_NN treatment_NN ._. The_DT entire_JJ procedure_NN was_VBD repeated_VBN in_IN 6_CD
          hours_NNS ,_, with_IN the_DT second_JJ aerosol_NN (_( either_CC saline_NN or_CC
          albuterol_NN )_) treatment_NN ._. None_NN of_IN the_DT patients_NNS received_VBD any_DT
          other_JJ bronchodilators_NNS within_IN 6_CD hours_NNS of_IN the_DT first_JJ aerosol_NN
          treatment_NN or_CC between_IN the_DT first_JJ and_CC second_JJ aerosol_NN
          administration_NN ._. In_IN those_DT infants_NNS who_WP were_VBD on_IN supplemental_JJ
          oxygen_NN ,_, the_DT amount_NN of_IN supplemental_JJ oxygen_NN was_VBD kept_VBN
          constant_JJ during_IN the_DT study_NN period_NN ._. Corticosteroids_NNP were_VBD
          not_RB administered_VBN to_TO any_DT patients_NNS in_IN the_DT study_NN ._.
        
        
          Pulmonary_NNP function_NN tests_NNS
          All_DT pulmonary_JJ function_NN tests_NNS were_VBD performed_VBN by_IN two_CD
          experienced_VBN respiratory_JJ therapists_NNS ._. A_DT SensorMedics_NNP 2600_CD
          Pediatric_NNP Pulmonary_NNP cart_NN (_( SensorMedics_NNP Corp_NNP ._. ,_, Anaheim_NNP ,_,
          CA_NNP ,_, USA_NNP )_) was_VBD used_VBN to_TO obtain_VB TBFV_NNP loops_NNS ._. The_DT TBFV_NNP loops_NNS
          were_VBD obtained_VBN and_CC analyzed_VBN by_IN a_DT standard_JJ method_NN described_VBD
          previously_RB [_NN 5_CD ]_NN ._. A_DT close-fitting_JJ face_NN mask_NN (_( Model_NNP
          VR-_NNP 3100_CD ;_: Ventlab_NNP Corporation_NNP ,_, Mocksville_NNP ,_, NC_NNP ,_, USA_NNP )_) with_IN
          an_DT air-inflated_JJ cuff_VB was_VBD used_VBN to_TO ensure_VB that_IN no_DT air_NN leaks_NNS
          occurred_VBD ._. Four_CD representative_NN tidal_JJ flow-volume_JJ loops_NNS
          were_VBD stored_VBN for_IN analysis_NN ._. Each_DT loop_NN was_VBD chosen_VBN from_IN a_DT
          series_NN of_IN breaths_NNS during_IN established_VBN tidal_JJ breathing_NN ._. A_DT
          minimum_NN of_IN 16_CD loops_NNS was_VBD collected_VBN to_TO select_VB the_DT four_CD
          stored_VBD loops_NNS ._. The_DT loops_NNS were_VBD selected_VBN from_IN tidal_JJ breaths_NNS ,_,
          with_IN as_IN stable_JJ a_DT volume_NN and_CC shape_NN as_IN possible_JJ ._. The_DT means_VBZ
          from_IN these_DT four_CD loops_NNS were_VBD used_VBN as_IN the_DT results_NNS for_IN each_DT
          child_NN ._.
        
        
          Outcome_NNP measures_NNS
          Several_JJ aspects_NNS of_IN pulmonary_JJ function_NN were_VBD chosen_VBN as_IN
          outcome_NN measures_NNS ._. These_DT included_VBD the_DT ratio_NN of_IN expiratory_NN
          time_NN to_TO reach_VB PTEF_NNP to_TO the_DT total_JJ expiratory_NN time_NN as_IN a_DT
          primary_JJ outcome_NN measure_NN ,_, the_DT tidal_JJ volume_NN (_( 
          V_NNP 
          T_NN )_) ,_, PTEF_NNP ,_, TEF_NNP 10_CD ,_, TEF_NNP 25_CD and_CC TEF_NNP 50_CD ,_, and_CC
          25_CD /_NN PT_NNP as_IN other_JJ pulmonary_JJ function_NN tests_NNS of_IN interest_NN ._.
          Heart_NNP rate_NN ,_, respiratory_JJ rate_NN ,_, oxygen_NN saturation_NN ,_, and_CC
          wheeze_NN score_NN (_( 0_CD =_SYM no_DT wheezing_VBG ;_: 1_CD =_SYM end-expiratory_JJ
          wheezing_VBG only_RB ;_: 2_CD =_SYM wheezing_VBG during_IN entire_JJ expiration_NN ±_NN
          inspiratory_NN phase_NN ,_, audible_JJ with_IN stethoscope_NN only_RB ;_: 3_CD =_SYM
          expiratory_NN and_CC inspiratory_NN wheezing_VBG audible_JJ without_IN
          stethoscope_NN )_) [_NN 20_CD ]_NN were_VBD also_RB measured_VBN ._.
        
        
          Statistical_NNP analysis_NN
          To_TO estimate_VB the_DT sample_NN size_NN ,_, we_PRP analyzed_VBD pulmonary_JJ
          function_NN studies_NNS of_IN 14_CD infants_NNS with_IN a_DT recent_JJ history_NN of_IN
          wheezing_VBG illness_NN that_WDT were_VBD performed_VBN in_IN our_PRP$ pulmonary_JJ
          function_NN laboratory_NN ._. We_PRP calculated_VBD the_DT intrasubject_NN
          coefficient_NN of_IN variation_NN for_IN 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP as_IN 20_CD -_: 25_CD %_NN ._. A_DT 40_CD %_NN difference_NN (_( twice_RB
          the_DT coefficient_NN of_IN variation_NN )_) was_VBD considered_VBN a_DT clinically_RB
          important_JJ improvement_NN ._. Assuming_VBG an_DT α_NN level_NN of_IN 0_CD ._. 05_CD
          (_( two-tailed_JJ )_) and_CC 90_CD %_NN power_NN ,_, a_DT sample_NN size_NN of_IN 17_CD -_: 20_CD
          patients_NNS per_IN group_NN was_VBD predicted_VBN ._. All_DT values_NNS are_VBP
          presented_VBN as_IN mean_NN ±_NN standard_JJ deviation_NN ._.
          Nineteen_NNP measurements_NNS were_VBD made_VBN all_DT together_RB in_IN each_DT
          of_IN the_DT two_CD categories_NNS (_( saline_NN treatment_NN and_CC albuterol_NN
          treatment_NN )_) ._. The_DT values_NNS for_IN each_DT investigated_VBN variable_NN
          were_VBD compared_VBN with_IN baseline_NN measurements_NNS (_( 19_CD measurements_NNS
          before_IN nebulization_NN with_IN saline_NN and_CC 19_CD measurements_NNS
          before_IN nebulization_NN with_IN albuterol_NN )_) by_IN repeated-measures_JJ
          analysis_NN of_IN variance_NN followed_VBN by_IN Bonferroni_NNP correction_NN
          for_IN multiple_JJ comparisons_NNS ._. These_DT comparisons_NNS included_VBD :_:
          baseline_NN before_IN saline_NN treatment_NN versus_CC baseline_NN before_IN
          albuterol_NN treatment_NN ;_: saline_NN treatment_NN versus_CC albuterol_NN
          treatment_NN ;_: baseline_NN before_IN saline_NN treatment_NN versus_CC saline_NN
          treatment_NN ;_: and_CC baseline_NN before_IN albuterol_NN treatment_NN versus_CC
          albuterol_NN treatment_NN ._. The_DT wheeze_NN scores_NNS in_IN various_JJ
          categories_NNS were_VBD compared_VBN with_IN a_DT non-parametric_JJ Friedman_NNP
          test_NN followed_VBN by_IN Dunn_NNP 's_POS test_NN ._. Improvement_NNP after_IN saline_NN
          treatment_NN and_CC albuterol_NN treatment_NN from_IN their_PRP$ respective_JJ
          baseline_NN values_NNS were_VBD compared_VBN with_IN a_DT paired_VBN 
          t_NN -_: test_NN ._. 
          P_NN <_NN 0_CD ._. 05_CD was_VBD considered_VBN
          significant_JJ ._.
        
      
      
        Results_NNS
        
          Patient_NNP characteristics_NNS
          Twenty_CD patients_NNS were_VBD enrolled_VBN in_IN the_DT study_NN during_IN the_DT
          study_NN period_NN ._. Analysis_NNP of_IN one_CD patient_NN 's_POS flow-volume_JJ loops_NNS
          was_VBD consistent_JJ with_IN grunting_VBG and_CC the_DT subject_NN was_VBD excluded_VBN
          from_IN the_DT study_NN ._. All_DT 19_CD infants_NNS in_IN our_PRP$ study_NN had_VBD a_DT cough_NN
          (_( 3_CD ._. 6_CD ±_NN 2_CD ._. 8_CD days_NNS )_) ._. Eighteen_CD infants_NNS had_VBD symptoms_NNS of_IN upper_JJ
          respiratory_JJ infection_NN (_( 2_CD ._. 94_CD ±_NN 0_CD ._. 9_CD days_NNS )_) ,_, wheezing_VBG (_( 2_CD ._. 3_LS ±_NN
          1_CD ._. 7_CD days_NNS )_) ,_, and_CC breathing_VBG difficulties_NNS (_( 1_CD ._. 7_CD ±_NN 0_CD ._. 9_CD days_NNS )_) ._.
          Sixteen_NNP infants_NNS had_VBD difficulties_NNS in_IN feeding_NN (_( 1_CD ._. 6_CD ±_NN 0_CD ._. 8_CD
          days_NNS )_) ,_, and_CC nine_CD of_IN the_DT 19_CD infants_NNS had_VBD fever_NN (_( 1_CD ._. 5_LS ±_NN 0_CD ._. 7_CD
          days_NNS )_) ._. A_DT family_NN history_NN of_IN wheezing_VBG or_CC atopy_NN was_VBD present_JJ
          in_IN nine_CD infants_NNS ._.
          Exposure_NNP to_TO passive_JJ smoking_NN and_CC household_NN pets_NNS were_VBD
          present_JJ in_IN 12_CD and_CC eight_CD infants_NNS ,_, respectively_RB ._. One_CD child_NN
          presented_VBN with_IN apnea_NN ,_, and_CC four_CD infants_NNS had_VBD otitis_NNS media_NNS
          at_IN the_DT time_NN of_IN admission_NN ._. The_DT duration_NN of_IN hospital_NN stay_NN
          in_IN our_PRP$ study_NN group_NN was_VBD 3_CD ._. 9_CD ±_NN 1_CD ._. 1_CD days_NNS ._. Five_CD infants_NNS
          received_VBD oxygen_NN supplementation_NN and_CC eight_CD infants_NNS needed_VBD
          intravenous_JJ fluids_NNS for_IN more_JJR than_IN 1_CD day_NN ._. All_DT infants_NNS were_VBD
          positive_JJ for_IN RSV_NNP and_CC none_NN were_VBD premature_JJ or_CC had_VBD
          bronchopulmonary_JJ dysplasia_NN ._.
          All_DT baseline_NN demographic_JJ and_CC clinical_JJ variables_NNS were_VBD
          evenly_RB distributed_VBN between_IN the_DT two_CD groups_NNS except_IN for_IN
          gender_NN distribution_NN (_( Table_NNP 1_LS )_) ._. No_DT significant_JJ changes_NNS
          were_VBD observed_VBN in_IN heart_NN rate_NN ,_, respiratory_JJ rate_NN ,_, oxygen_NN
          saturation_NN ,_, and_CC wheeze_NN score_NN after_IN aerosol_NN treatments_NNS
          (_( Table_NNP 2_LS )_) ._. The_DT PTEF_NNP increased_VBN both_DT after_IN albuterol_NN and_CC
          saline_NN treatments_NNS but_CC the_DT difference_NN between_IN the_DT two_CD
          treatments_NNS was_VBD not_RB significant_JJ ._. Both_DT TEF_NNP 10_CD and_CC 25_CD /_NN PT_NNP
          significantly_RB decreased_VBD after_IN albuterol_NN administration_NN (_( 
          P_NN <_NN 0_CD ._. 05_CD )_) ._. There_EX were_VBD no_DT
          significant_JJ changes_NNS in_IN 
          V_NNP 
          PTEF_NNP /_NN 
          V_NNP 
          E_NNP and_CC 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP either_CC with_IN albuterol_NN or_CC with_IN saline_NN
          (_( Table_NNP 3_LS )_) ._.
        
      
      
        Discussion_NNP
        
          Relationship_NNP between_IN tidal_JJ flow_NN indices_NNS and_CC airflow_NN
          obstruction_NN
          Morris_NNP and_CC Lane_NNP [_NN 8_CD ]_NN demonstrated_VBN that_IN ,_, in_IN older_JJR
          children_NNS and_CC adults_NNS ,_, 
          V_NNP 
          PTEF_NNP /_NN 
          V_NNP 
          E_NNP and_CC 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP values_NNS from_IN TBFV_NNP loops_NNS correlate_VBP
          well_RB with_IN specific_JJ airway_NN conductance_NN ,_, with_IN forced_VBN
          expiratory_NN volume_NN in_IN the_DT first_JJ second_NN ,_, and_CC with_IN the_DT ratio_NN
          of_IN forced_VBN expiratory_NN volume_NN in_IN the_DT first_JJ second_NN to_TO the_DT
          forced_VBN vital_JJ capacity_NN ._. They_PRP also_RB showed_VBD that_IN the_DT values_NNS
          of_IN 
          V_NNP 
          PTEF_NNP /_NN 
          V_NNP 
          E_NNP and_CC 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP were_VBD significantly_RB lower_JJR in_IN subjects_NNS
          with_IN obstructive_JJ airway_NN disease_NN ._.
          In_IN children_NNS younger_JJR than_IN 2_CD years_NNS of_IN age_NN with_IN
          bronchopulmonary_JJ obstruction_NN ,_, 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP and_CC 
          V_NNP 
          PTEF_NNP /_NN 
          V_NNP 
          E_NNP values_NNS were_VBD lower_JJR than_IN in_IN the_DT
          controls_NNS and_CC improved_VBN after_IN salbutamol_NN administration_NN [_NN
          7_CD ]_NN ._. The_DT magnitude_NN of_IN change_NN in_IN 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP was_VBD significantly_RB correlated_JJ with_IN
          the_DT concentration_NN of_IN serum_NN eosinophilic_JJ cationic_JJ protein_NN
          (_( an_DT inflammatory_JJ marker_NN )_) [_NN 7_CD ]_NN ._. The_DT same_JJ investigators_NNS
          showed_VBD ,_, in_IN a_DT different_JJ study_NN ,_, that_IN 
          V_NNP 
          PTEF_NNP /_NN 
          V_NNP 
          E_NNP ,_, 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP and_CC 25_CD /_NN PT_NNP ratios_NNS were_VBD significantly_RB
          lower_JJR in_IN asthmatic_JJ children_NNS and_CC improved_VBN significantly_RB
          after_IN salbutamol_NN when_WRB compared_VBN with_IN controls_NNS [_NN 24_CD ]_NN ._. In_IN
          another_DT study_NN in_IN school-age_JJ children_NNS ,_, however_RB ,_, the_DT 
          V_NNP 
          PTEF_NNP /_NN 
          V_NNP 
          E_NNP value_NN was_VBD not_RB significantly_RB
          different_JJ in_IN asymptomatic_JJ asthmatics_NNS when_WRB compared_VBN with_IN
          age-matched_JJ healthy_JJ controls_NNS [_NN 14_CD ]_NN ._. In_IN addition_NN ,_, forced_VBD
          vital_JJ capacity_NN ,_, peak_NN expiratory_NN flow_NN (_( by_IN spirometry_NN )_) ,_, and_CC
          forced_VBD expiratory_NN flow_NN at_IN 75_CD %_NN of_IN forced_VBN vital_JJ capacity_NN
          (_( FEF_NNP 
          75_CD %_NN )_) were_VBD similar_JJ in_IN both_DT groups_NNS ._.
          Only_RB FEF_NNP 
          50_CD %_NN and_CC FEF_NNP 
          25_CD %_NN discriminated_JJ asymptomatic_JJ
          asthmatics_NNS from_IN the_DT healthy_JJ controls_NNS ._.
          The_DT tidal_JJ flow_NN index_NN ,_, 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP ,_, measured_VBN during_IN the_DT first_JJ 3_CD months_NNS
          of_IN life_NN ,_, has_VBZ been_VBN shown_VBN to_TO be_VB predictive_JJ of_IN subsequent_JJ
          wheezing_VBG in_IN boys_NNS during_IN the_DT first_JJ 3_CD years_NNS [_NN 9_CD ,_, 10_CD ]_NN ._. Alder_NNP
          
          et_CC al_NN ._. [_NN 13_CD ]_NN ,_, however_RB ,_, concluded_VBD
          in_IN their_PRP$ study_NN that_DT 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP is_VBZ only_RB weakly_RB associated_VBN with_IN the_DT
          development_NN of_IN lower_JJR respiratory_JJ tract_NN illness_NN during_IN the_DT
          first_JJ year_NN of_IN life_NN ,_, and_CC the_DT ratio_NN is_VBZ less_RBR precise_JJ and_CC an_DT
          epidemiologically_RB less_RBR useful_JJ measure_NN than_IN maximum_NN
          expiratory_NN flow_NN at_IN functional_JJ residual_JJ capacity_NN ._. Clarke_NNP 
          et_CC al_NN ._. [_NN 25_CD ]_NN were_VBD also_RB not_RB able_JJ to_TO
          detect_VB any_DT difference_NN in_IN 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP between_IN healthy_JJ infants_NNS who_WP did_VBD and_CC
          did_VBD not_RB develop_VB lower_JJR respiratory_JJ illness_NN ._.
          In_IN older_JJR infants_NNS (_( aged_VBN 6_CD -_: 14_CD months_NNS )_) who_WP suffered_VBD from_IN
          obstructive_JJ airway_NN disease_NN ,_, Banovcin_NNP 
          et_CC al_NN ._. [_NN 6_CD ]_NN reported_VBD significant_JJ
          correlation_NN between_IN maximum_NN expiratory_NN flow_NN at_IN functional_JJ
          residual_JJ capacity_NN corrected_VBN for_IN lung_NN volume_NN and_CC 
          V_NNP 
          PTEF_NNP /_NN 
          V_NNP 
          E_NNP and_CC 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP ._. They_PRP also_RB showed_VBD a_DT weak_JJ
          correlation_NN between_IN 
          V_NNP 
          PTEF_NNP /_NN 
          V_NNP 
          E_NNP and_CC airway_NN resistance_NN ,_, reported_VBD as_IN
          percentage_NN predicted_VBD [_NN 6_CD ]_NN ._. Banovcin_NNP 
          et_CC al_NN ._. concluded_VBD that_IN 
          V_NNP 
          PTEF_NNP /_NN 
          V_NNP 
          E_NNP and_CC 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP correlate_VBP better_JJR with_IN measures_NNS of_IN
          peripheral_JJ airway_NN obstruction_NN than_IN with_IN airway_NN resistance_NN
          reflecting_VBG mainly_RB central_JJ airway_NN patency_NN ._. Dezateaux_NNP 
          et_CC al_NN ._. [_NN 12_CD ]_NN compared_VBD 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP with_IN airway_NN function_NN measured_VBN by_IN
          plethysmography_NN ._. They_PRP found_VBD a_DT weak_JJ but_CC significant_JJ
          association_NN between_IN 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP and_CC specific_JJ airway_NN conductance_NN in_IN
          infants_NNS aged_VBN older_JJR than_IN 3_CD months_NNS ,_, irrespective_RB of_IN their_PRP$
          previous_JJ wheezing_VBG status_NN ._.
          What_WP determines_VBZ the_DT 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP value_NN ?_. There_EX is_VBZ controversy_NN in_IN
          infants_NNS about_IN the_DT validity_NN of_IN tests_NNS to_TO measure_VB airway_NN
          obstruction_NN [_NN 26_CD ]_NN ._. Little_NNP is_VBZ known_VBN about_IN the_DT determinants_NNS
          of_IN 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP in_IN infancy_NN ._. The_DT relationship_NN of_IN 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP to_TO lung_NN function_NN may_MD exist_VB because_IN 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP quantifies_NNS the_DT degree_NN of_IN active_JJ
          tidal_JJ slowing_NN that_WDT occurs_VBZ in_IN response_NN to_TO respiratory_JJ
          system_NN mechanics_NNS ._. In_IN normal_JJ subjects_NNS ,_, during_IN expiration_NN ,_,
          the_DT peak_NN flow_NN is_VBZ reached_VBN approximately_RB one-third_NN of_IN the_DT
          way_NN through_IN the_DT expiration_NN ._. This_DT is_VBZ because_IN of_IN the_DT slow_JJ
          cessation_NN of_IN inspiratory_NN muscle_NN activity_NN at_IN the_DT end_NN of_IN
          inspiration_NN ._. If_IN the_DT inspiratory_NN muscle_NN activity_NN ceases_VBZ
          abruptly_RB at_IN the_DT end_NN of_IN inspiration_NN ,_, completely_RB passive_JJ
          expiration_NN results_NNS in_IN early_JJ peaking_VBG of_IN the_DT flow_NN due_JJ to_TO
          unopposed_JJ recoil_NN of_IN the_DT lung_NN and_CC the_DT chest_NN wall_NN ._.
          Both_DT 
          t_NN 
          PTEF_NNP and_CC 
          t_NN 
          E_NNP will_MD influence_VB the_DT final_JJ value_NN of_IN
          the_DT ratio_NN 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP ._. In_IN a_DT patient_NN with_IN airway_NN
          obstruction_NN ,_, slow_JJ exhalation_NN secondary_JJ to_TO an_DT increased_VBN
          expiration_NN time_NN constant_JJ will_MD increase_VB 
          t_NN 
          E_NNP ._. In_IN addition_NN ,_, active_JJ breaking_NN is_VBZ
          diminished_VBN ,_, leading_VBG to_TO decreased_VBD 
          t_NN 
          PTEF_NNP ._. Both_DT these_DT mechanisms_NNS result_VBP in_IN
          a_DT low_JJ 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP value_NN in_IN a_DT patient_NN with_IN airway_NN
          obstruction_NN ._. This_DT effect_NN could_MD be_VB further_RBR increased_VBN in_IN
          severe_JJ obstruction_NN with_IN active_JJ exhalation_NN and_CC no_DT active_JJ
          breaking_NN ._. In_IN other_JJ words_NNS ,_, 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP may_MD not_RB be_VB a_DT direct_JJ indicator_NN of_IN
          airway_NN caliber_NN ,_, but_CC may_MD reflect_VB a_DT neuromuscular_NN response_NN
          to_TO respiratory_JJ mechanics_NNS in_IN airway_NN obstruction_NN ._.
          The_DT behavior_NN of_IN 
          V_NNP 
          PTEF_NNP /_NN 
          V_NNP 
          E_NNP mainly_RB parallels_VBZ that_IN of_IN 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP ._. The_DT same_JJ mechanisms_NNS responsible_JJ
          for_IN determining_VBG 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP may_MD be_VB operative_JJ in_IN determining_VBG 
          V_NNP 
          PTEF_NNP /_NN 
          V_NNP 
          E_NNP ._. The_DT role_NN of_IN several_JJ measured_VBN tidal_JJ
          flows_NNS (_( TEF_NNP 50_CD ,_, TEF_NNP 25_CD ,_, TEF_NNP 10_CD )_) and_CC ratios_NNS (_( 25_CD /_NN PT_NNP )_) in_IN the_DT
          evaluation_NN of_IN pulmonary_JJ function_NN is_VBZ mostly_RB unknown_JJ ._. In_IN
          airway_NN obstruction_NN ,_, tidal_JJ flows_NNS may_MD become_VB flow_NN limited_JJ ,_,
          especially_RB towards_IN the_DT end_NN of_IN the_DT tidal_JJ volume_NN ,_, because_IN
          of_IN dynamic_JJ compression_NN [_NN 8_CD ]_NN ._. The_DT rate_NN of_IN airflow_NN is_VBZ
          highly_RB dependent_JJ on_IN the_DT lung_NN volume_NN at_IN which_WDT the_DT flow_NN is_VBZ
          measured_VBN ._. Without_IN knowing_VBG the_DT lung_NN volumes_NNS at_IN which_WDT the_DT
          tidal_JJ flows_NNS are_VBP measured_VBN ,_, the_DT tidal_JJ flows_NNS have_VBP limited_JJ
          value_NN in_IN the_DT evaluation_NN of_IN lung_NN function_NN ._.
        
        
          Tidal_NNP breathing_VBG parameters_NNS and_CC bronchiolitis_NNS
          Low_NNP 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP values_NNS in_IN infants_NNS with_IN bronchiolitis_NNS
          may_MD result_VB from_IN an_DT increased_VBN time_NN constant_JJ (_( i_NNP ._. e_SYM ._.
          increased_VBN 
          t_NN 
          E_NNP )_) and_CC /_NN or_CC decreased_VBD active_JJ braking_VBG
          (_( i_NNP ._. e_SYM ._. reduced_VBN 
          t_NN 
          PTEF_NNP )_) ._. Both_DT of_IN these_DT changes_NNS can_MD
          happen_VB because_IN of_IN airway_NN obstruction_NN ._. Theoretically_RB ,_,
          sedation_NN may_MD reduce_VB 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP by_IN diminishing_VBG active_JJ braking_VBG ._. In_IN
          fact_NN ,_, 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP was_VBD found_VBN to_TO be_VB lower_JJR in_IN awake_JJ
          compared_VBN with_IN sleeping_VBG newborn_JJ infants_NNS [_NN 11_CD ]_NN ._. The_DT mean_JJ
          value_NN for_IN 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP (_( 0_CD ._. 16_CD ±_NN 0_CD ._. 09_CD )_) in_IN our_PRP$ study_NN is_VBZ lower_JJR
          than_IN that_DT previously_RB reported_VBD values_NNS for_IN healthy_JJ infants_NNS
          [_NN 10_CD ,_, 15_CD ,_, 27_CD ]_NN ._. The_DT probable_JJ explanation_NN for_IN the_DT low_JJ
          values_NNS of_IN 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP in_IN our_PRP$ study_NN population_NN is_VBZ airway_NN
          obstruction_NN ._.
          In_IN our_PRP$ study_NN ,_, PTEFs_NNP have_VBP increased_VBN with_IN the_DT
          concomitant_NN decrease_NN in_IN tidal_JJ flows_NNS near_IN the_DT end_NN of_IN
          exhalation_NN (_( TEF_NNP 10_CD )_) and_CC with_IN the_DT decrease_NN in_IN the_DT 25_CD /_NN PT_NNP
          ratio_NN ._. Peak_NNP flow_NN during_IN tidal_JJ breathing_NN is_VBZ submaximal_NN ;_: it_PRP
          can_MD be_VB increased_VBN with_IN increased_VBN effort_NN ._. Theoretically_RB ,_, it_PRP
          can_MD also_RB increase_VB due_JJ to_TO bronchodilation_NN ._. We_PRP cannot_NN
          determine_VB whether_IN bronchodilation_NN or_CC increased_VBN force_NN of_IN
          contraction_NN of_IN respiratory_JJ muscles_NNS resulting_VBG from_IN aerosol_NN
          administration_NN is_VBZ the_DT cause_NN of_IN the_DT increased_VBN PTEF_NNP in_IN the_DT
          present_JJ patients_NNS ._.
          The_DT later_RB in_IN expiration_NN that_IN the_DT flow_NN is_VBZ measured_VBN ,_, the_DT
          more_JJR the_DT measurement_NN reflects_VBZ the_DT resistance_NN of_IN the_DT very_RB
          small_JJ airways_NNS [_NN 28_CD ]_NN ._. A_DT significant_JJ decrease_NN in_IN tidal_JJ
          expiratory_NN flows_NNS at_IN the_DT remaining_VBG 10_CD %_NN of_IN tidal_JJ volume_NN in_IN
          the_DT present_JJ study_NN may_MD suggest_VB narrowing_VBG of_IN the_DT small_JJ
          airways_NNS after_IN albuterol_NN administration_NN ._. The_DT ratio_NN 25_CD /_NN PT_NNP
          will_MD be_VB influenced_VBN by_IN the_DT values_NNS of_IN TEF_NNP 25_CD as_RB well_RB as_IN
          PTEF_NNP ._. In_IN the_DT present_JJ study_NN ,_, PTEF_NNP significantly_RB increased_VBD
          and_CC TEF_NNP 25_CD decreased_VBD (_( although_IN not_RB statistically_RB
          significant_JJ )_) after_IN albuterol_NN administration_NN ._. Both_DT these_DT
          changes_NNS have_VBP lead_VBN to_TO significant_JJ decrease_NN in_IN the_DT ratio_NN of_IN
          25_CD /_NN PT_NNP ._. Increased_VBN effort_NN during_IN exhalation_NN can_MD
          theoretically_RB lead_VB to_TO an_DT increase_NN in_IN PTEF_NNP and_CC ,_, by_IN dynamic_JJ
          compression_NN of_IN smaller_JJR airways_NNS ,_, to_TO a_DT decrease_NN in_IN TEF_NNP 25_CD ;_:
          this_DT leads_VBZ to_TO a_DT decrease_NN in_IN 25_CD /_NN PT_NNP ._. The_DT resistance_NN of_IN
          small_JJ airways_NNS is_VBZ believed_VBN to_TO have_VB a_DT greater_JJR effect_NN on_IN
          flow_NN at_IN lower_JJR lung_NN volumes_NNS [_NN 28_CD ]_NN ._. Although_IN tidal_JJ volumes_NNS
          remained_VBD constant_JJ in_IN the_DT present_JJ study_NN ,_, we_PRP do_VBP not_RB know_VB
          whether_IN the_DT expiratory_NN flows_NNS at_IN the_DT remaining_VBG 10_CD %_NN of_IN
          tidal_JJ volume_NN were_VBD measured_VBN at_IN identical_JJ lung_NN volumes_NNS
          before_IN and_CC after_IN aerosol_NN treatment_NN ._.
          The_DT lack_NN of_IN improvement_NN of_IN tidal_JJ flow_NN indices_NNS of_IN
          airflow_NN obstruction_NN in_IN the_DT present_JJ study_NN may_MD be_VB because_IN
          of_IN a_DT true_JJ absence_NN of_IN bronchodilation_NN in_IN these_DT patients_NNS ,_,
          or_CC because_IN these_DT indices_NNS are_VBP not_RB sensitive_JJ enough_RB to_TO
          detect_VB bronchodilation_NN if_IN one_CD existed_VBD ._. As_IN the_DT index_NN 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP reflects_VBZ the_DT neuromuscular_NN response_NN
          of_IN pulmonary_JJ mechanics_NNS ,_, it_PRP may_MD not_RB be_VB sensitive_JJ enough_RB to_TO
          detect_VB small_JJ changes_NNS in_IN the_DT airway_NN caliber_NN ._. As_IN we_PRP have_VBP
          not_RB compared_VBN TBFV_NNP indices_NNS with_IN conventional_JJ measures_NNS of_IN
          airway_NN obstruction_NN ,_, we_PRP cannot_NN be_VB certain_JJ whether_IN we_PRP have_VBP
          missed_VBN bronchodilation_NN ,_, if_IN one_CD existed_VBD ._.
          The_DT small_JJ sample_NN size_NN and_CC variability_NN of_IN the_DT tidal_JJ
          flow_NN indices_NNS might_MD have_VB also_RB contributed_VBN to_TO the_DT negative_JJ
          results_NNS of_IN the_DT present_JJ study_NN ._. The_DT power_NN of_IN the_DT study_NN was_VBD
          to_TO detect_VB 40_CD %_NN improvement_NN in_IN 
          t_NN 
          PTEF_NNP /_NN 
          t_NN 
          E_NNP ._. We_PRP could_MD have_VB easily_RB missed_VBN a_DT much_RB
          smaller_JJR response_NN because_IN of_IN the_DT sample_NN size_NN ,_, although_IN the_DT
          clinical_JJ significance_NN of_IN such_JJ a_DT response_NN is_VBZ unknown_JJ ._. We_PRP
          have_VBP only_RB used_VBN a_DT single_JJ dose_NN of_IN aerosol_NN and_CC measured_VBD the_DT
          pulmonary_JJ function_NN once_RB after_IN the_DT aerosol_NN administration_NN ._.
          Theoretically_RB ,_, we_PRP may_MD have_VB missed_VBN a_DT peak_NN effect_NN of_IN
          bronchodilation_NN ._. Although_IN we_PRP have_VBP used_VBN a_DT standard_JJ method_NN
          of_IN aerosol_NN delivery_NN and_CC a_DT standard_JJ dose_NN ,_, altered_VBD
          respiratory_JJ mechanics_NNS and_CC small-airway_JJ disease_NN in_IN these_DT
          infants_NNS with_IN bronchiolitis_NNS may_MD have_VB lead_VBN to_TO a_DT decrease_NN in_IN
          the_DT delivered_VBN dose_NN of_IN bronchodilator_NN ,_, resulting_VBG in_IN a_DT lack_NN
          of_IN response_NN ._.
        
        
          Clinical_NNP scores_NNS in_IN bronchiolitis_NNS
          In_IN recent_JJ years_NNS there_RB have_VBP been_VBN several_JJ reports_NNS of_IN
          improvement_NN of_IN clinical_JJ scores_NNS such_JJ as_IN oxygen_NN saturation_NN
          and_CC respiratory_JJ distress_NN scores_NNS ,_, etc_FW ._. ,_, after_IN
          bronchodilator_NN administration_NN in_IN infants_NNS with_IN
          bronchiolitis_NNS [_NN 19_CD ,_, 20_CD ]_NN ._. The_DT failure_NN of_IN clinical_JJ scores_NNS
          to_TO improve_VB in_IN the_DT present_JJ study_NN may_MD be_VB because_IN of_IN the_DT
          small_JJ sample_NN size_NN and_CC the_DT inclusion_NN of_IN patients_NNS with_IN mild_JJ
          disease_NN ._. However_RB ,_, the_DT observed_VBN improvement_NN in_IN clinical_JJ
          scores_NNS in_IN several_JJ previous_JJ studies_NNS may_MD be_VB due_JJ to_TO
          mechanisms_NNS other_JJ than_IN bronchodilation_NN ._. Transient_NNP
          improvement_NN in_IN oxygenation_NN may_MD have_VB occurred_VBN because_IN of_IN
          increased_VBN minute_NN ventilation_NN secondary_JJ to_TO alteration_NN in_IN
          tidal_JJ breathing_NN pattern_NN following_VBG aerosol_NN administration_NN
          without_IN bronchodi-lation_JJ ._. An_DT improvement_NN in_IN respiratory_JJ
          distress_NN scores_NNS may_MD be_VB explained_VBN by_IN an_DT increase_NN in_IN nasal_NN
          and_CC upper_JJ airway_NN caliber_NN ,_, especially_RB in_IN the_DT studies_NNS with_IN
          epinephrine_NN ._. In_IN the_DT present_JJ study_NN group_NN ,_, there_EX was_VBD no_DT
          clinical_JJ improvement_NN with_IN a_DT bronchodilator_NN ._. The_DT
          bronchodilators_NNS may_MD increase_VB oxygen_NN consumption_NN ,_,
          precipitate_NN paradoxical_JJ hypoxemia_NN ,_, and_CC increase_VB the_DT cost_NN
          of_IN hospitalization_NN ._.
        
      
      
        Conclusions_NNP
        This_DT present_JJ study_NN in_IN infants_NNS with_IN mild_JJ bronchiolitis_NNS
        due_JJ to_TO RSV_NNP demonstrates_VBZ that_IN nebulized_JJ albuterol_NN does_VBZ not_RB
        improve_VB 
        V_NNP 
        PTEF_NNP /_NN 
        V_NNP 
        E_NNP and_CC 
        t_NN 
        PTEF_NNP /_NN 
        t_NN 
        E_NNP ,_, but_CC can_MD decrease_VB TEF_NNP 10_CD and_CC
        25_CD /_NN PT_NNP ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Abbreviations_NNP
        25_CD /_NN PT_NNP =_SYM the_DT ratio_NN of_IN tidal_JJ expiratory_NN flow_NN at_IN 25_CD %_NN of_IN the_DT
        remaining_VBG tidal_JJ volume_NN to_TO peak_VB tidal_JJ expiratory_NN flow_NN ;_: PTEF_NNP
        =_SYM peak_NN tidal_JJ expiratory_NN flow_NN ;_: RSV_NNP =_SYM respiratory_JJ syncytial_NN
        virus_NN ;_: TBFV_NNP =_SYM tidal_JJ breathing_NN flow_NN volume_NN ;_: TEF_NNP 10_CD =_SYM tidal_JJ
        expiratory_NN flow_NN at_IN 10_CD %_NN of_IN the_DT remaining_VBG tidal_JJ volume_NN ;_: TEF_NNP 25_CD
        =_SYM tidal_JJ expiratory_NN flow_NN at_IN 25_CD %_NN of_IN the_DT remaining_VBG tidal_JJ
        volume_NN ;_: TEF_NNP 50_CD =_SYM tidal_JJ expiratory_NN flow_NN at_IN 50_CD %_NN of_IN the_DT
        remaining_VBG tidal_JJ volume_NN ;_: 
        t_NN 
        PTEF_NNP /_NN 
        t_NN 
        E_NNP =_SYM the_DT fraction_NN of_IN exhaled_VBD time_NN to_TO
        achieve_VB peak_NN tidal_JJ expiratory_NN flow_NN to_TO total_VB expiratory_NN
        time_NN ;_: 
        V_NNP 
        PTEF_NNP /_NN 
        V_NNP 
        E_NNP =_SYM the_DT fraction_NN of_IN exhaled_VBD volume_NN to_TO
        achieve_VB peak_NN tidal_JJ expiratory_NN flow_NN to_TO total_VB expiratory_NN
        tidal_JJ volume_NN ._.
      
    
  
